ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
University of Sydney at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University of Sydney takes part in 4 sessions at ESMO 2026 in Madrid. Its work spans breast, prostate and skin cancers, alongside tumour testing. It examines ways to improve DNA testing success, reports overall survival results for fulvestrant and ipatasertib in metastatic breast cancer, and considers BRAF as a marker in early melanoma.
| Organization | ESMO 2026 Attendance |
|---|---|
University of Sydney Sydney, Australia | |
Public research university in Sydney, Australia, with a medical school and a national clinical trials centre. | Poster Fri Oct 23 13:00–15:00 Adjust amplifiable FFPE DNA inputs to improve first-pass NGS success rate in solid tumours Biomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Small-cell neuroendocrine prostate cancer (SCNEPC) emerging after starting treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304) Sarcoma, CNS, head & neck and rare cancersGenitourinary cancers Abstract Sat Oct 24 08:40–08:50 Talk Mon Oct 26 08:30–08:45 |
Find decision makers at University of Sydney
Tell us what you sell and we’ll find the people at University of Sydney most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction